Navigation Links
Blockbuster Expectations Don't Always Translate to Market Reality
Date:4/9/2013

LONDON and BOSTON, April 9, 2013 /PRNewswire/ --

EP Vantage Analyzes Accuracy of Analyst Sales Estimates for Blockbuster and Near-Blockbuster Launches

Pharma industry observers widely expect Biogen Idec's new multiple sclerosis therapy Tecfidera to reach mega-blockbuster status. However, EP Vantage®, EvaluatePharma®'s award-winning editorial team cautions that forecasting revenue for an unlaunched drug isn't always easy. A five-year review of EvaluatePharma's consensus forecasts of analyst predictions for blockbuster or near-blockbuster drug launches found that new products with the biggest hopes often disappoint, while others have vastly outperformed low expectations.

The report, "The Industry's Brightest Hopes: Where Are They Now?" uncovers some remarkable misses prompted by a sea change in treatment, reimbursement issues, safety concerns and heightened competition. While analysts' forecasts don't always ring true on performance, EP Vantage found that forecasts have also been spot on and in some cases performances even exceeded initial estimates.

"Evaluating the accuracy of consensus forecasts is particularly pertinent given the recent US approval of Tecfidera, with consensus data suggesting that this drug's sales could reach $3.7 billion within five years. Many factors can influence the success of a drug and while forecasts have been proven to ring true in many cases, our analysis shows just how far off they can be," commented Jacob Plieth , author of the EP Vantage report.

As the first company to provide consensus forecasts on global drug sales, EvaluatePharma takes the unweighted average of up to six equity research forecasts to provide reliable consensus estimates for the pharma and biotech industries to 2018. By taking an average, the impact of outlying forecasts is mitigated.

For a look at which of 2013's launches will be the next blockbusters, read the analysis here.

About EP Vantage

Written by a team of award winning pharma journalists, EP Vantage provides daily financial analysis of key industry catalysts including: regulatory and patent decisions, marketing approvals, licensing deals, and M&A - giving fresh angles and insight to both current and future industry triggers.

Launched in 2007 by EvaluatePharma, EP Vantage's unique access to EvaluatePharma data allows unrivaled, forward-looking, coverage of the pharmaceutical and biotech industry.

To register for a free trial of EP Vantage please visit: https://www.epvantage.com/Secure/Registration.aspx.

About Evaluate Ltd.

Since 1996, EvaluatePharma has been the premier source for high quality life science sector analysis, delivering exclusive consensus forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the global clinical trial landscape.  A team of over 85 dedicated healthcare analysts employ rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.EvaluatePharma.com.

Media Contacts:
EP Vantage EvaluatePharma
Christine Lindgren
+1-617-866-3906
christine.lindgren@evaluategroup.com

Chempetitive Group (for US media)
Rachel Lear
+1-781-775-3640
rlear@chempetitive.com


'/>"/>
SOURCE EP Vantage
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
2. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
3. Area Radiology Groups Brand Makeover Redefines Customer Experience Expectations in Healthcare
4. Fluke Biomedical launches six translated websites
5. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Ophthalmic Drugs: World Market Prospects 2012-2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017   MedPlast, Inc. ... device industry, announced today that it has signed ... Device Manufacturing Services business.   The acquisition broadens ... as a leading services provider to the world,s ... will further expand the company,s capabilities in assembly ...
(Date:2/20/2017)... Provides understanding and access to the ... by the worlds leading healthcare companies. Download ... The Global Renal Failure Partnering Terms and Agreements ... partnering deals and agreements entered into by the ... in partnering deals - Top deals by ...
(Date:2/20/2017)... NEW YORK , Feb. 20, 2017 ... imaging technique that creates detailed images of the organs ... a magnetic field and radio waves. The technique does ... the study of brain function or growth of cancer. ... such as neurology, cardiology, oncology, musculoskeletal, and orthopedics. Hence, ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... 21, 2017 , ... Hanna Boys Center http://www.hannacenter.org ... the keynote speaker at its second Professional Networking Breakfast on March 9, 2017. ... comprehensive strategies to create and expand opportunities for boys and young men of ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas ... around Tarrant County, is embarking on a six month charity event aimed at raising ... cancer. , Cancer is one of the deadliest diseases in America; more than 7.5 ...
(Date:2/21/2017)... ... February 21, 2017 , ... Each February ... History Month (officially African American History Month ). This month-long ... of a diverse race of people, but also the opportunity to examine the ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on ... loss. It found that the treatments have led to significant improvements in weight loss ... unassisted efforts. It also noted very few problematic results relating to the treatment. Beverly ...
(Date:2/20/2017)... OAK BROOK. Ill. (PRWEB) , ... February 20, 2017 , ... ... at high risk–according to a new study from Germany published online in the journal ... cancer screening modality that offers better sensitivity than mammography and ultrasound. Currently, guidelines reserve ...
Breaking Medicine News(10 mins):